OptiNose (OPTN) Misses Q4 EPS by 14c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. ANET
6. DUOL
7. SWKS
8. XYZ
9. CVS
10. FISV

Go back to OptiNose (OPTN) Misses Q4 EPS by 14c

Optinose Reports Fourth Quarter and Full Year 2017 Financial Results and Recent Operational Highlights

March 13, 2018 7:00 AM EDT

Optinose expects early April availability of XHANCE in retail pharmacies

XHANCE Xperience program launched in early March

YARDLEY, Pa., March 13, 2018 (GLOBE NEWSWIRE) -- Optinose (NASDAQ: OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported financial results for the quarter and year ended December 31, 2017, and provided recent operational highlights.

2017 was a transformational year for Optinose, and 2018 is poised to be even better as we make XHANCE available to the... More